Transfer of hepatocellular microRNA regulates cytochrome P450 2E1 in renal tubular cells.


Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 07 08 2020
revised: 07 10 2020
accepted: 09 10 2020
pubmed: 25 11 2020
medline: 25 8 2021
entrez: 24 11 2020
Statut: ppublish

Résumé

Extracellular microRNAs enter kidney cells and modify gene expression. We used a Dicer-hepatocyte-specific microRNA conditional-knock-out (Dicer-CKO) mouse to investigate microRNA transfer from liver to kidney. Dicer Dicer-CKO mice demonstrated a decrease in kidney miR-122 in the absence of other microRNA changes. During hepatotoxicity, miR-122 increased in kidney tubular cells; this was abolished in Dicer-CKO mice. Depletion of hepatocyte microRNA increased kidney cytochrome P450 2E1 expression and activity. Serum ECVs from mice with hepatotoxicity increased proximal tubular cell miR-122 and prevented cisplatin toxicity. miR-122 increased in urinary ECVs during human hepatotoxicity. Transfer of microRNA was not restricted to liver injury -miR-499 was released following cardiac injury and correlated with an increase in the kidney. Physiological transfer of functional microRNA to the kidney is increased by liver injury and this signalling represents a new paradigm for understanding the relationship between liver injury and renal function. Kidney Research UK, Medical Research Scotland, Medical Research Council.

Sections du résumé

BACKGROUND BACKGROUND
Extracellular microRNAs enter kidney cells and modify gene expression. We used a Dicer-hepatocyte-specific microRNA conditional-knock-out (Dicer-CKO) mouse to investigate microRNA transfer from liver to kidney.
METHODS METHODS
Dicer
FINDINGS RESULTS
Dicer-CKO mice demonstrated a decrease in kidney miR-122 in the absence of other microRNA changes. During hepatotoxicity, miR-122 increased in kidney tubular cells; this was abolished in Dicer-CKO mice. Depletion of hepatocyte microRNA increased kidney cytochrome P450 2E1 expression and activity. Serum ECVs from mice with hepatotoxicity increased proximal tubular cell miR-122 and prevented cisplatin toxicity. miR-122 increased in urinary ECVs during human hepatotoxicity. Transfer of microRNA was not restricted to liver injury -miR-499 was released following cardiac injury and correlated with an increase in the kidney.
INTERPRETATION CONCLUSIONS
Physiological transfer of functional microRNA to the kidney is increased by liver injury and this signalling represents a new paradigm for understanding the relationship between liver injury and renal function.
FUNDING BACKGROUND
Kidney Research UK, Medical Research Scotland, Medical Research Council.

Identifiants

pubmed: 33232872
pii: S2352-3964(20)30468-0
doi: 10.1016/j.ebiom.2020.103092
pmc: PMC7689533
pii:
doi:

Substances chimiques

MicroRNAs 0
Mirn122 microRNA, mouse 0
Cytochrome P-450 CYP2E1 EC 1.14.13.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103092

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Author JWD is a member of the expert advisory group for the EU IMI funded TransBioLine Consortium. Author LD supervises a PhD studentship co-funded by Regulus Therapeutics and GSK.

Auteurs

Olivia Matthews (O)

Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, United Kingdom.

Emma E Morrison (EE)

Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, United Kingdom.

John D Tranter (JD)

Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, United Kingdom.

Philip Starkey Lewis (P)

Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, United Kingdom.

Iqbal S Toor (IS)

Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, United Kingdom.

Abhishek Srivastava (A)

AstraZeneca, Clinical Pharmacology & Safety Sciences Department, Biopharmaceuticals Science Unit, Darwin Building 310, Cambridge Science Park, Milton Rd, Cambridge, CB4 0FZ. United Kingdom.

Rebecca Sargeant (R)

AstraZeneca, Clinical Pharmacology & Safety Sciences Department, Biopharmaceuticals Science Unit, Darwin Building 310, Cambridge Science Park, Milton Rd, Cambridge, CB4 0FZ. United Kingdom.

Helen Rollison (H)

AstraZeneca, Clinical Pharmacology & Safety Sciences Department, Biopharmaceuticals Science Unit, Darwin Building 310, Cambridge Science Park, Milton Rd, Cambridge, CB4 0FZ. United Kingdom.

Kylie P Matchett (KP)

Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, United Kingdom.

Timothy J Kendall (TJ)

Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, United Kingdom.

Gillian A Gray (GA)

Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, United Kingdom.

Chris Goldring (C)

Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, United Kingdom.

Kevin Park (K)

Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, United Kingdom.

Laura Denby (L)

Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, United Kingdom.

Neeraj Dhaun (N)

Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, United Kingdom.

Matthew A Bailey (MA)

Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, United Kingdom.

Neil C Henderson (NC)

Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, United Kingdom; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, United Kingdom.

Dominic Williams (D)

AstraZeneca, Clinical Pharmacology & Safety Sciences Department, Biopharmaceuticals Science Unit, Darwin Building 310, Cambridge Science Park, Milton Rd, Cambridge, CB4 0FZ. United Kingdom.

James W Dear (JW)

Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, United Kingdom. Electronic address: james.dear@ed.ac.uk.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH